TriSalus Life Sciences, Inc.
TLSI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $12 | $11 | $9 | $8 |
| % Growth | 3.1% | 22.3% | 11% | – |
| Cost of Goods Sold | $2 | $2 | $1 | $1 |
| Gross Profit | $10 | $9 | $8 | $7 |
| % Margin | 83.5% | 83.9% | 83.7% | 85.3% |
| R&D Expenses | $5 | $4 | $3 | $3 |
| G&A Expenses | $7 | $6 | $5 | $5 |
| SG&A Expenses | $13 | $13 | $12 | $12 |
| Sales & Mktg Exp. | $7 | $7 | $7 | $7 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $19 | $17 | $15 | $15 |
| Operating Income | -$9 | -$7 | -$7 | -$8 |
| % Margin | -77.9% | -65.4% | -79.9% | -91.8% |
| Other Income/Exp. Net | -$2 | -$1 | -$3 | -$3 |
| Pre-Tax Income | -$11 | -$8 | -$10 | -$10 |
| Tax Expense | $0 | -$0 | $0 | -$0 |
| Net Income | -$11 | -$8 | -$10 | -$10 |
| % Margin | -93.5% | -73.9% | -113.2% | -122.4% |
| EPS | -0.96 | -0.27 | -0.39 | -0.41 |
| % Growth | -255.6% | 30.8% | 4.9% | – |
| EPS Diluted | -0.96 | -0.27 | -0.39 | -0.41 |
| Weighted Avg Shares Out | 43 | 33 | 29 | 27 |
| Weighted Avg Shares Out Dil | 43 | 33 | 29 | 27 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$9 | -$7 | -$9 | -$9 |
| % Margin | -79.4% | -59.8% | -98.1% | -107.1% |